Nath Bio-Genes (India) Board of Directors

Get the latest insights into the leadership at Nath Bio-Genes (India). Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Satish Kagliwal Managing Director
Mr. Madhukar Deshpande Director
Ms. Ashu Jain Director
Mrs. Jeevanlata Kagliwal Director
Mr. Vadla Nagabhushanam Director
Mr. Hitesh Purohit Director
Mr. Akash Kagliwal Director

Nath Bio-Genes (India) Share price

NATHBIOGEN

168.98

0.22 (-0.13%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:59 IST
BUYSELL
Today's High

172.00

Today's Low

168.00

52 Week Low

137.55

52 Week High

238.69

The current prices are delayed, login to your account for live prices

Nath Bio-Genes (India) FAQs

The board at Nath Bio-Genes (India) consists of experienced professionals, including Mr. Satish Kagliwal , Mr. Madhukar Deshpande , and others, overseeing the company’s strategic and corporate governance.

Directors at Nath Bio-Genes (India) are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Satish Kagliwal is the current chairman at Nath Bio-Genes (India).

Executive directors at Nath Bio-Genes (India) are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Nath Bio-Genes (India) adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Nath Bio-Genes (India), board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.